Denali Therapeutics Inc
Research Denali Therapeutics Inc (DNLI) on Bullrun: market cap USD 4.11B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDNLI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 4.11B
- Financial periodFY2025
- Net income-USD 512.54M
- Free cash flow-USD 422.10M
Valuation Snapshot
latest market cap is USD 4.11B.
About Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A);
Frequently asked questions
What is Denali Therapeutics Inc's market cap?
Denali Therapeutics Inc's market capitalization is USD 4.11B.
What does Denali Therapeutics Inc do?
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases;